Announcement on Change of Subsidiary's Drug Production License
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced a change in its subsidiary's drug production license. The subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received approval to expand its production range. This change is expected to enhance the management of export drugs and maintain stable production supply. The company noted that this license update will not have a significant impact on its current performance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix
Earlier from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Resolutions of the 34th Meeting of the 9th Board of Directors
- Announcement on Recognition of Subsidiary as High-tech Enterprise
- Announcement on Branch Receiving Pharmaceutical Registration Certificate in Macau
- Special Report on Deposit, Management and Actual Use of Raised Funds in 2025
- Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Later from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Election of Board of Directors at Expiry of Term of Office
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subsidiary
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Election of Employee Representative Director
- Announcement on Completing Term Change of the Board of Directors and Appointing Senior Management Members
Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Baiyunshan Pharmaceutical